Inactive Instrument

Highlights Liminal BioSciences Inc. Toronto S.E.

Equities

LMNL

CA53272L1031

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. completed the acquisition of remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2).	23-09-25	CI
Liminal BioSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Liminal BioSciences Agrees to Be Acquired by Structured Alpha for $8.50 per Share; Shares Soar Pre-Bell	23-07-12	MT
Liminal BioSciences Provides R&D Update	23-06-02	CI
Liminal BioSciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Liminal BioSciences Shares Soar on Structured Alpha Takeover Bid	23-04-05	MT
Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. entered into a non-binding proposal to acquire remaining 35.97% stake in Liminal BioSciences Inc. (DB:PJ2) for $8.4 million.	23-04-04	CI
Liminal Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Liminal BioSciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Liminal BioSciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Ocugen, Inc. cancelled the acquisition of a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N).	22-09-29	CI
Liminal BioSciences Terminates Legacy Contract of Former Plasma-Derived Therapeutics Business	22-08-25	MT
Liminal BioSciences Inc. Announces Termination of Legacy CDMO Contract	22-08-25	CI
Liminal BioSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Liminal BioSciences Inc. (DB:PJ2N) acquired the remaining 23% stake in Pathogen Removal and Diagnostic Technologies, Inc. for $30.	22-08-09	CI
Liminal BioSciences Inc. Announces Discontinuation of Fezagepras Development	22-07-21	CI
Liminal Biosciences Announces First Subject Dosed in Phase 1A Single Ascending Dose Clinical Trial of Fezagepras	22-05-23	CI
Liminal BioSciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Liminal BioSciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-17	CI
Liminal Biosciences Provides Update on its Lead Drug Candidate Fezagepras	22-03-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Liminal BioSciences Inc. Toronto S.E.

Equities

LMNL

CA53272L1031

Highlights

Filters